Why This Summit Is Unmissable for Biotech Drug Developers
Advance Your RNA-Targeted Small Molecule Programs With Insights From Industry Leaders.
Whether you're validating new RNA targets, advancing lead compounds, or progressing toward IND-enabling studies, this is the only forum dedicated exclusively to RNA-targeted small molecules.
Join the companies leading the field as they share new data, lessons learned, and emerging strategies across splice modulation, RNA degradation, direct RNA binding, covalent targeting, epitranscriptomics, and condensate biology. You'll gain practical insight into what's working, what's failing, and where the field is heading next.
Challenges We Help Solve
Identifying Functional RNA Targets Worth Pursuing
Move beyond target ligandability alone and understand how leading teams are selecting RNA targets with the greatest biological relevance, tractability, and therapeutic potential.
Expanding Beyond Splice Modulation
Discover how innovators are leveraging direct RNA binding, RNA degradation, translation inhibition, covalent binders, condensate biology, and epitranscriptomics to unlock new therapeutic opportunities.
Overcoming Selectivity Challenges
Learn how organizations are assessing target engagement, off-target effects, and functional activity to build confidence in candidate progression.
Finding Novel Chemical Space
Benchmark strategies for exploring chemically diverse scaffolds and avoiding increasingly crowded and competitive RNA-targeting chemistry landscapes.
Advancing Programs Toward the Clinic
Hear lessons learned from companies moving from discovery into preclinical and clinical development to de-risk your own development strategy.
Priority Sessions for Biotech Teams
Identifying Functional RNA Targets at Scale
Workshop A: Identifying Functional RNA Targets at Scale to Prioritize Therapeutically Relevant Discovery Hypothesis
Speakers:
- Dalya Gartzman, Chief Executive Officer & Co-Founder, Renasis Bio
- Dominic Reynolds, Chief Scientific Officer, Remix Therapeutics
- Stefan Schiesser, Director, Medicinal Chemistry, AstraZeneca
Discover how leading biotech teams are distinguishing biologically meaningful RNA targets from targets that are simply ligandable, while implementing scalable approaches to improve discovery success and reduce wasted screening efforts.
Expanding RNA-Focused Chemical Space
Workshop C: Exploring RNA-Focused Chemical Space Beyond Known Chemotypes to Inspire New Hit Discovery Strategies
Speakers:
- Lukasz Olenginski, Senior Scientist, Screening & Assay Development, Molecular Horizon
- Robert Batey, Professor, University of Colorado Boulder
Learn how innovators are breaking away from crowded RNA-targeting chemistry, discovering novel scaffolds, and creating differentiated opportunities across splice modulation, degradation, translation inhibition, and direct RNA binding programs.
Advancing RNA-Targeted Programs Toward the Clinic
Conference Day One: Advancing Oral Splice-Modulating Small Molecules Toward Clinical Development for Rare Neurodegenerative Diseases
Speaker:
- Sridhar Narayan, Vice President, Medicinal Chemistry, ReviR Therapeutics
Gain practical insights into optimizing activity, selectivity, and translational confidence while navigating the progression of RNA-targeted small molecules from discovery toward IND-enabling studies and clinical evaluation.
Benchmark Your Strategy Against Peers
Questions you could ask your peers to benchmark against them:
How are they identifying functionally relevant versus merely ligandable targets?
What screening approaches are generating the most actionable hits?
How are teams assessing selectivity before entering development?
Which emerging modalities are attracting the most investment?
What evidence is needed to convince pharma partners?
What Past Attendees Say
This meeting is the main chance each year for all of the thought leaders in drugging RNA with small molecules to get in one room and exchange ideas. If you want to know what the latest approaches are to cracking the RNA-drugging problem, you’ll find them here.
The summit was both informative and inspiring, giving me valuable insights and ideas that I can bring back to my own work.
Explore the Agenda
Hear the latest industry advances in RNA target selection, structure-guided design, selective modulation and translational strategies across the full RNA-targeted small molecule pipeline and during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Connect with RNA-targeted small molecule leaders across discovery, preclinical and clinical development during our dedicated networking sessions to exchange insights, build collaborations and strengthen decisions from target selection to therapeutic impact.